China National Accord Medicines 미래 성장

Future 기준 확인 1/6

China National Accord Medicines (는) 각각 연간 6.1% 및 5.9% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 5.4% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 8.2% 로 예상됩니다.

주요 정보

6.1%

수익 성장률

5.4%

EPS 성장률

Healthcare 수익 성장	22.9%
매출 성장률	5.9%
향후 자기자본 수익률	8.2%
애널리스트 커버리지	Good
마지막 업데이트	20 Dec 2024

최근 미래 성장 업데이트

China National Accord Medicines Corporation Ltd. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Oct 30

Analysts Are Updating Their China National Accord Medicines Corporation Ltd. (SZSE:000028) Estimates After Its Full-Year Results

Apr 10

Recent updates

Lacklustre Performance Is Driving China National Accord Medicines Corporation Ltd.'s (SZSE:000028) Low P/E

Nov 18

China National Accord Medicines Corporation Ltd. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Oct 30

China National Accord Medicines (SZSE:000028) Seems To Use Debt Quite Sensibly

Oct 10

China National Accord Medicines Corporation Ltd.'s (SZSE:000028) Low P/E No Reason For Excitement

Aug 13

Estimating The Intrinsic Value Of China National Accord Medicines Corporation Ltd. (SZSE:000028)

Jul 12

Is China National Accord Medicines (SZSE:000028) A Risky Investment?

Jun 12

Improved Earnings Required Before China National Accord Medicines Corporation Ltd. (SZSE:000028) Shares Find Their Feet

May 12

Analysts Are Updating Their China National Accord Medicines Corporation Ltd. (SZSE:000028) Estimates After Its Full-Year Results

Apr 10

China National Accord Medicines Corporation Ltd. (SZSE:000028) Shares Could Be 28% Below Their Intrinsic Value Estimate

Mar 15

China National Accord Medicines (SZSE:000028) Has A Rock Solid Balance Sheet

Feb 29

수익 및 매출 성장 예측

SZSE:000028 - 애널리스트의 미래 추정치 및 과거 재무 데이터 (CNY Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2026	85,583	1,705	N/A	1,700	6
12/31/2025	82,070	1,599	N/A	1,650	7
12/31/2024	76,379	1,536	N/A	1,680	5
9/30/2024	75,358	1,475	2,452	2,753	N/A
6/30/2024	74,876	1,512	2,073	2,380	N/A
3/31/2024	75,881	1,626	1,769	2,093	N/A
12/31/2023	75,477	1,599	2,615	2,937	N/A
9/30/2023	75,412	1,629	1,656	1,968	N/A
6/30/2023	75,702	1,643	2,674	3,005	N/A
3/31/2023	74,979	1,597	2,672	2,988	N/A
12/31/2022	73,443	1,487	2,238	2,560	N/A
9/30/2022	72,765	1,310	1,931	2,293	N/A
6/30/2022	71,324	1,269	1,098	1,467	N/A
3/31/2022	69,459	1,260	1,360	1,744	N/A
12/31/2021	68,358	1,336	1,285	1,655	N/A
9/30/2021	66,979	1,478	592	939	N/A
6/30/2021	65,643	1,500	970	1,294	N/A
3/31/2021	62,875	1,482	1,579	1,884	N/A
12/31/2020	59,649	1,402	1,209	1,503	N/A
9/30/2020	56,244	1,306	2,663	2,937	N/A
6/30/2020	54,358	1,262	2,058	2,312	N/A
3/31/2020	53,539	1,217	1,865	2,113	N/A
12/31/2019	52,787	1,268	1,761	2,013	N/A
9/30/2019	50,779	1,243	1,546	1,817	N/A
6/30/2019	47,943	1,218	1,965	2,236	N/A
3/31/2019	44,937	1,217	1,140	1,399	N/A
12/31/2018	43,122	1,211	1,067	1,323	N/A
9/30/2018	41,751	1,182	1,110	1,338	N/A
6/30/2018	41,517	1,143	N/A	1,282	N/A
3/31/2018	41,298	1,078	N/A	923	N/A
12/31/2017	41,263	1,058	N/A	1,285	N/A
9/30/2017	41,418	1,080	N/A	1,155	N/A
6/30/2017	41,211	1,084	N/A	871	N/A
3/31/2017	41,159	1,205	N/A	959	N/A
12/31/2016	41,248	1,187	N/A	1,472	N/A
9/30/2016	49,249	1,263	N/A	1,878	N/A
6/30/2016	45,568	1,199	N/A	1,839	N/A
3/31/2016	41,870	984	N/A	1,286	N/A
12/31/2015	37,819	928	N/A	1,457	N/A
9/30/2015	25,740	721	N/A	201	N/A
6/30/2015	25,155	693	N/A	136	N/A
3/31/2015	24,683	682	N/A	-189	N/A
12/31/2014	23,954	652	N/A	-797	N/A
9/30/2014	23,418	629	N/A	-369	N/A
6/30/2014	22,680	607	N/A	-258	N/A
3/31/2014	21,864	545	N/A	-70	N/A
12/31/2013	21,199	520	N/A	465	N/A

애널리스트 미래 성장 예측

수입 대 저축률: 000028 의 연간 예상 수익 증가율( 6.1% )이 saving rate( 2.8% 보다 높습니다. ).

수익 vs 시장: 000028 의 연간 수익( 6.1% ) CN 시장( 25.5% 보다 느리게 성장할 것으로 예상됩니다. 25.5% 연간).

고성장 수익: 000028 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.

수익 대 시장: 000028 의 수익(연간 5.9% ) CN 시장( 13.7% 보다 느리게 성장할 것으로 예상됩니다. 13.7% 연간).

고성장 수익: 000028 의 수익(연간 5.9% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: 000028 의 자본 수익률은 3년 내에 최저 수준이 될 것으로 예상됩니다( 8.2 %).

성장 기업 발견

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2024/12/29 06:01
장 마감 주가	2024/12/27 00:00
수익	2024/09/30
연간 수익	2023/12/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.

애널리스트 출처

China National Accord Medicines Corporation Ltd. 26 애널리스트 중 7 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Lei Tian	AJ Securities Co., Ltd
Shuchang Liu	Changjiang Securities Co. LTD.
Yanyin Zhu	China International Capital Corporation Limited

China National Accord Medicines 미래 성장

Future 기준 확인 1/6

주요 정보

최근 미래 성장 업데이트

China National Accord Medicines Corporation Ltd. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Consensus EPS estimates fall by 14%

Price target decreased by 8.4% to CN¥35.86

Analysts Are Updating Their China National Accord Medicines Corporation Ltd. (SZSE:000028) Estimates After Its Full-Year Results

Price target decreased by 11% to CN¥36.44

Price target decreased by 10% to CN¥42.49

Recent updates

Lacklustre Performance Is Driving China National Accord Medicines Corporation Ltd.'s (SZSE:000028) Low P/E

China National Accord Medicines Corporation Ltd. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Third quarter 2024 earnings: EPS misses analyst expectations

China National Accord Medicines (SZSE:000028) Seems To Use Debt Quite Sensibly

China National Accord Medicines Corporation Ltd. to Report Q3, 2024 Results on Oct 29, 2024

Investor sentiment improves as stock rises 19%

Consensus EPS estimates fall by 14%

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased by 8.4% to CN¥35.86

China National Accord Medicines Corporation Ltd.'s (SZSE:000028) Low P/E No Reason For Excitement

High number of new directors

Estimating The Intrinsic Value Of China National Accord Medicines Corporation Ltd. (SZSE:000028)

Insufficient new directors

China National Accord Medicines Corporation Ltd. to Report First Half, 2024 Results on Aug 28, 2024

China National Accord Medicines Corporation Ltd. Announces Final Cash Dividend on B Shares for the Year 2023, Payable on 27 June 2024

Is China National Accord Medicines (SZSE:000028) A Risky Investment?

Improved Earnings Required Before China National Accord Medicines Corporation Ltd. (SZSE:000028) Shares Find Their Feet

China National Accord Medicines Corporation Ltd. Approves Cash Dividend for the Year 2023

Now 20% overvalued after recent price rise

Analysts Are Updating Their China National Accord Medicines Corporation Ltd. (SZSE:000028) Estimates After Its Full-Year Results

Full year 2023 earnings: EPS and revenues miss analyst expectations

China National Accord Medicines Corporation Ltd., Annual General Meeting, May 08, 2024

China National Accord Medicines Corporation Ltd. to Report Q1, 2024 Results on Apr 30, 2024

China National Accord Medicines Corporation Ltd. (SZSE:000028) Shares Could Be 28% Below Their Intrinsic Value Estimate

China National Accord Medicines (SZSE:000028) Has A Rock Solid Balance Sheet

Investor sentiment improves as stock rises 17%

China National Accord Medicines Corporation Ltd. to Report Fiscal Year 2023 Results on Mar 30, 2024

Now 20% undervalued after recent price drop

Price target decreased by 11% to CN¥36.44

Now 22% undervalued after recent price drop

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Price target decreased by 10% to CN¥42.49

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target increased by 16% to CN¥42.59

Full year 2022 earnings released: EPS: CN¥3.47 (vs CN¥3.12 in FY 2021)

Investor sentiment improves as stock rises 18%

Price target increased by 7.0% to CN¥38.16

Now 21% undervalued

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Second quarter 2022 earnings released: EPS: CN¥0.98 (vs CN¥0.96 in 2Q 2021)

China National Accord Medicines Corporation Ltd. Announces 2021 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on June 17, 2022

Price target decreased to CN¥38.17

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

China National Accord Medicines Corporation Ltd. Approves Final Cash Dividend for the Year 2021

China National Accord Medicines Corporation Ltd., Annual General Meeting, Apr 22, 2022

China National Accord Medicines Corporation Ltd. Proposes Final Cash Dividend for the Year 2021

Consensus forecasts updated

Full year 2021 earnings: EPS misses analyst expectations

Third quarter 2021 earnings released

Second quarter 2021 earnings released: EPS CN¥0.96 (vs CN¥0.92 in 2Q 2020)

Price target decreased to CN¥52.97

High number of new directors

Upcoming dividend of CN¥0.80 per share

First quarter 2021 earnings released: EPS CN¥0.77 (vs CN¥0.58 in 1Q 2020)

Consensus forecasts updated

Full year 2020 earnings released: EPS CN¥3.27 (vs CN¥2.97 in FY 2019)

China National Accord Medicines Corporation Ltd. to Report Fiscal Year 2020 Results on Apr 16, 2021

New 90-day low: CN¥41.98

New 90-day low: CN¥46.01

New 90-day high: CN¥51.91

Price target raised to CN¥60.27

Third quarter earnings released

China National Accord Medicines Corporation Ltd. to Report Q3, 2020 Results on Oct 22, 2020

First half earnings released

Earnings released

China National Accord Medicines Corporation Ltd. to Report First Half, 2020 Results on Aug 29, 2020

New 90-day high - CN¥51.20

수익 및 매출 성장 예측

애널리스트 미래 성장 예측